LRRC56: A Potential Drug Target for Stem Cell and Cell Survival

Target Name: LRRC56

NCBI ID: G115399

LRRC56

LRRC56: A Potential Drug Target for Stem Cell and Cell Survival

LRRC56 (CILD39) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the long non-coding RNA (lncRNA) family, which includes around 200,000 known lncRNAs in humans . LRRC56 has been shown to play a role in the regulation of stem cell proliferation and has potential as a drug target in various diseases.

The LRRC56 protein is composed of 255 amino acid residues and has a calculated molecular weight of 31.1 kDa. It is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to be present in neural stem cells, heart muscle cells, and glomerular filtration units. LRRC56 is a good candidate for a drug target due to its unique structure and the various functions it has been shown to play in different organisms.

One of the functions of LRRC56 is its role in the regulation of stem cell proliferation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body. LRRC56 has been shown to play a role in the self -renewal and proliferation of stem cells. Studies have shown that LRRC56 can promote the growth and proliferation of stem cells in various cultures and that it can also inhibit the differentiation of stem cells into different types of cells. These properties make LRRC56 an attractive drug target for diseases that are characterized by the over-expression of stem cells.

Another function of LRRC56 is its role in the regulation of cell survival. Stem cells have a unique ability to survive and divide without being cell cycle restricted like normal cells. LRRC56 plays a role in this process by regulating the expression of genes that are necessary for cell survival. Studies have shown that LRRC56 can inhibit the execution of the p53 pathway, a well-known mechanism for cell survival, in stem cells. This suggests that LRRC56 may be a useful drug target for diseases that are characterized by the over-expression of stem cells and the execution of the p53 pathway.

LRRC56 has also been shown to play a role in the regulation of inflammation. Inflammation is a natural response of the immune system to injury or infection. LRRC56 has also been shown to play a role in the regulation of the production of pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, in various organisms. This suggests that LRRC56 may be a useful drug target for diseases that are characterized by the over-expression of inflammation.

In addition to its functions in stem cell proliferation and inflammation, LRRC56 has also been shown to play a role in the regulation of the immune system. LRRC56 is a part of the immune system and has been shown to play a role in the regulation of immune cell function and the production of antibodies. This suggests that LRRC56 may be a useful drug target for diseases that are characterized by the over-expression of the immune system.

LRRC56 is also a good candidate as a drug target due to its unique structure and the various functions it has been shown to play in different organisms. LRRC56 is a small protein that has four known functions, including the regulation of stem cell proliferation, the regulation of cell survival, the regulation of inflammation, and the regulation of the immune system. This makes LRRC56 an attractive drug target for diseases that are characterized by the over-expression of these processes.

In conclusion, LRRC56 is a protein that has been shown to play a number of roles in various organisms. Its unique structure and diverse functions make it an attractive candidate for a drug target. Further research is needed to fully understand the functions of LRRC56 and its potential as a drug

Protein Name: Leucine Rich Repeat Containing 56

Functions: Required for the assembly of dynein arms

The "LRRC56 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC56 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets